Migraine Jabs and Miscarriage: What New Research Tells Women

If you rely on monthly migraine jabs to keep headaches at bay, a landmark study just gave you something new to discuss with your doctor — especially if pregnancy might be in your future. Researchers have found that a widely used class of migraine-prevention drugs was tied to a meaningfully higher risk of miscarriage when taken during early pregnancy, and the findings are already reshaping how experts counsel patients.

The research, according to a peer-reviewed paper in JAMA Neurology published on October 12, 2026, analyzed close to seven thousand six hundred pregnancies among just over seven thousand women aged fifteen to forty-five who had been diagnosed with migraine before becoming pregnant. Compared with women who were not exposed to the drugs, those who used them during early pregnancy faced an adjusted risk of miscarriage that was higher by roughly two-fifths. The paper was authored by a team led by Dr Leah Flatman of the Centre Hospitalier Universitaire Sainte-Justine in Montreal.

What the study found

The investigation drew on a United States commercial insurance claims database and followed pregnancies through the twentieth week. Scientists split participants into three groups: women receiving the injected migraine drugs, women taking the beta-blocker propranolol, and women on no migraine medication at all. The headline result was that miscarriage risk climbed more steeply among women on the injections.

When the team presented the work at a national headache medicine conference in Florida in June 2026, they reported that losses in the first trimester occurred in about five percent of pregnancies among women using the injections, compared with roughly two percent among those taking propranolol alone, according to Medscape's report of the presentation. The older beta-blocker, in contrast, showed no signal of increased risk. A standardized analysis in the published paper estimated the absolute difference at just over four percentage points — the authors' way of saying the elevated relative risk translates into a smaller number of extra losses per hundred pregnancies.

The drug class at the center of the findings is the calcitonin gene-related peptide, or CGRP, monoclonal antibodies — injected treatments marketed under names such as Aimovig, Ajovy, Emgality and Vyepti. Dr Flatman, the study's lead investigator, told conference attendees that the takeaway is caution rather than alarm: "These results support cautious use of anti-CGRP therapies and emphasize the importance of preconception counseling for women of childbearing potential. They also highlight the need for future safety research of pregnancy, including studies of fetal and long-term offspring outcomes."

Why this matters to young women

Migraine is one of the most common chronic conditions among women in their teens, twenties and thirties — precisely the age range where pregnancy is most likely to be on the table. These popular migraine jabs have been marketed as a lifestyle fix: once-monthly shots or quarterly infusions that can cut migraine days dramatically for people who have cycled through older preventives with poor results. Millions of prescriptions have been written since the first of these drugs cleared the US Food and Drug Administration in 2018, which means a large population of women of childbearing age is now using them.

Here is the practical catch. These antibody drugs linger in the body for months because of their long half-lives, so stopping the moment a pregnancy test turns positive may not remove the exposure. That is why the researchers stress preconception counseling — talking to your neurologist about pregnancy plans before conception, rather than after. In the United Kingdom, health guidance already advises that these drugs should not be used by women who are pregnant or planning to try for a baby, and this new human data gives that caution a stronger evidence base. Because the antibodies circulate for so long, expert guidance on migraine management during pregnancy has gone further and recommends that women stop the injections at least five months before trying to conceive — a detail many patients first hear about in the doctor's office rather than the pharmacy.

Keeping the risk in perspective

A few important caveats keep the picture balanced. The study was observational and retrospective, drawing on claims records rather than a controlled trial, and the data ran only through 2021, when relatively few exposed pregnancies existed. The researchers also could not capture the very earliest pregnancy losses, and they acknowledge that women prescribed the injections tended to have markers of more severe migraine — a potential confounder, though the association held up across multiple sensitivity analyses.

It is also worth remembering that untreated migraine carries its own pregnancy risks, a point specialists make often in our ongoing health coverage. Poorly controlled migraines have been linked to higher rates of preeclampsia, preterm birth and miscarriage, so abandoning treatment without a plan is not the lesson here. Experts say the takeaway is a conversation, not a verdict: if you are on one of these injections and there is any chance you could become pregnant, ask your doctor about timing, contraception and alternatives like propranolol, which showed no such signal. The science is young, but for the first time, women of childbearing potential have human data to weigh — and that is exactly what informed choice looks like.